

1 **Category of paper:** Original articles

2

3 **Manuscript title:** Increased risks of upper tract urothelial carcinoma in male and female

4 Chinese herbalists

5

6 **Short running title:** Urothelial carcinoma in herbalists

7

8 **Authors:** Hsiao-Yu Yang, MD, MSc,<sup>1,2</sup> Jung-Der Wang, MD, PhD,<sup>2,4</sup> Tsai-Chang Lo, MD,

9 MSc<sup>3</sup> and Pau-Chung Chen, MD, PhD<sup>2</sup>

10 楊孝友,<sup>1,2</sup> 王榮德,<sup>2,4</sup> 羅財璋,<sup>3</sup> 陳保中<sup>2</sup>

11

12 **Institution:**

13 <sup>1</sup> Department of Occupational Medicine, Buddhist Tzu Chi General Hospital, Tzu Chi

14 University, Hualien, Taiwan

15 <sup>2</sup> Institute of Occupational Medicine and Industrial Hygiene, National Taiwan University

16 College of Public Health, Taipei, Taiwan

17 <sup>3</sup> Public Health Bureau, Miaoli, Taiwan

18 <sup>4</sup> Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

19 <sup>1</sup> 慈濟醫院家庭醫學暨職業醫學科

1   <sup>2</sup> 台灣大學職業醫學與工業衛生研究所

2   <sup>3</sup> 苗栗縣政府衛生局

3   <sup>4</sup> 臺大醫院內科

4

5   **Name and address for correspondence:**

6   Dr. Pau-Chung Chen

7   Institute of Occupational Medicine and Industrial Hygiene, National Taiwan University College

8   of Public Health, 17 Xuzhou Road, Taipei 100, Taiwan

9   +886-2-3366 8088 (Office)

10   +886-2-2358 2402 (Fax)

11   pchen@ntu.edu.tw.

12   陳保中

13   台灣大學職業醫學與工業衛生研究所

14   100 台北市徐州路 17 號

15

16

1 **ABSTRACT**

2 **Background/Purpose:** It has been shown that herbs containing aristolochic acid (AA) induce  
3 urological cancer. Chinese herbalists have easy access to herbs containing AA. Our previous  
4 mortality study showed a significantly increased risk of urological cancer in female but not  
5 male herbalists. To re-examine this risk in male herbalists, the incidences of urological  
6 cancers were analyzed.

7 **Methods:** All Chinese herbalists in Taiwan (6550 herbalists) registered during 1985–2000  
8 were enrolled, and we retrospectively followed the development of cancers until 2001 by  
9 analysis of data collected from the Taiwan Cancer Registry. Standardized incidence ratios  
10 (SIRs) were calculated for urological cancers in herbalists and compared with those for  
11 urological cancers in the general population in Taiwan.

12 **Results:** There were 30 newly-diagnosed cases of urological cancers and most of them were  
13 transitional cell carcinoma (93.1%). The mean age at diagnosis for urothelial carcinoma was  
14 51.6 years, and 51.9% were in the upper urinary tract. After adjustment for age and gender,  
15 the SIR for all urological cancers was 3.51 (95% CI 2.37- 5.01). When stratified by location,  
16 the SIRs for kidney and upper urinary tract cancers, and bladder cancer were 4.24 (95% CI  
17 2.47- 6.80) and 2.86 (95% CI 1.52- 4.89), respectively. When analyzed by gender, the SIRs  
18 for all urological cancers, kidney and upper urinary tract cancers, and bladder cancer were  
19 also significantly increased in male herbalists.

1 **Conclusion:** The significantly increased risk of urological cancer in male herbalists raises the  
2 possibility that this disease is work-related.

3

4 **Key words:** Chinese herbal drugs, Chinese herbalist, aristolochic acid, urothelial carcinoma,  
5 urological cancer.

6

7

8

## 1 **Introduction**

2 Herbs have been used extensively throughout the world and all during human history.<sup>1</sup>  
3 Chinese herbal drugs are not only used in China but also in Taiwan, Korea, Japan and Hong  
4 Kong.<sup>2-5</sup> An important reason for such extensive usage is that people believe herbal drugs are  
5 mild and harmless.<sup>6</sup> In Taiwan, Chinese medicine is covered by National Health Insurance,  
6 which regularly reimburses the costs of Chinese herbal products.<sup>7, 8</sup> In 1993, Vanherweghem  
7 and his colleagues first reported that many young women who took Chinese herbs containing  
8 aristolochic acids (AA) developed renal failure and urothelial carcinoma.<sup>9</sup> AA has been found  
9 in many Chinese herbs.<sup>10-13</sup> Although nephropathy and urothelial carcinoma related to the use  
10 of herbs had been reported in Belgium, Hong Kong, China and Taiwan<sup>9, 14-17</sup>, the  
11 occupational risks in Chinese herbalists have rarely been studied.<sup>18</sup> Herbalism is an ancient  
12 form of healing in Chinese society. Herbalists are not formally educated or trained in  
13 conventional medical or pharmacy schools. Instead, the knowledge of Chinese medicine  
14 passed down from generation to generation by the “master and apprentice” system. Herbalists  
15 as an occupational group have the greatest access to Chinese herbs.<sup>19</sup>

16 Our previous studies based on analysis of data from the Taiwan National Mortality  
17 Registry Database found that female herbalists had a higher mortality risk of both urological  
18 cancer and chronic kidney diseases. But in male herbalists, the increased risk was only  
19 significant for chronic kidney disease, not for urological cancer.<sup>18</sup> The mortality rate was

1 associated with the quality of the health care system, and patients with urological cancer had  
2 an 11-year life expectancy in Taiwan.<sup>20</sup> Since patients possibly die from another cause (not  
3 mentioned in the mortality registry which in addition does not contain pathology reports) than  
4 urological cancer, the use of these registers in our previous study might have led us to  
5 underestimate the risk of urothelial malignancy in male herbalists.

6 To examine whether the risk of urological cancer is increased in male Chinese herbalists,  
7 this study analyzed data from the National Cancer Registry.

8

## 9 **Material and Methods**

10 In Taiwan, the Labor Insurance Program began in 1960 and all workers aged 15 to 60  
11 years are required to join. The Chinese Herbalist Union was established in 1985, and most  
12 herbalists in Taiwan who work in traditional Chinese herbal stores are members. In this study,  
13 we enrolled all Chinese Herbalist Union members who were insured under the Labor  
14 Insurance Program between 1985 and 2000. Date of birth, gender and employment history  
15 were obtained from the Bureau of Labor Insurance (BLI) database. Any case of missing data  
16 or coding error, such as the date of cancer diagnosis earlier than the date of first employment,  
17 was excluded from further analysis.

18 Because some herbalists might have started to work in herbal stores before 1985 and  
19 many had begun to work after they completed their 9-year elementary school education or

1 were 15 years old, we defined the start of occupational exposure to herbs as age 15 years and  
2 the end of exposure as the date of departure from the union, occurrence of cancer, or the end  
3 of observation period.

4 The occurrence of cancer, date of diagnosis, histological pattern and cancer site coded in  
5 ICD-9 were obtained from the Taiwan Cancer Registry. The registry is a population-based  
6 cancer registry established in 1979 and funded by the Department of Health. Hospitals with  
7 more than 50-bed capacity that provide outpatient and hospitalized cancer care are expected  
8 to report all newly diagnosed malignant neoplasm to the registry.<sup>21</sup> For comparability, we  
9 converted all the ICD-9 diagnosis codes to ICD-10 codes.<sup>22</sup> We followed the development of  
10 cancers to the end of 2001. The study protocol was approved by the Ethics Committee of the  
11 National Taiwan University College of Public Health before commencement.

## 12 **Statistical analysis**

13 We used the PC Life Table Analysis System (LTAS)<sup>22</sup> Version 1.0d, developed by the  
14 National Institute for Occupational Safety and Health, to calculate (via indirect  
15 standardization methods) the standardized incidence ratio (SIR) for each cancer. The  
16 observed number of cancers was compared with the expected number of cancers within every  
17 five-year stratum. The expected number was computed by multiplying the gender-, age-, and  
18 calendar-time-specific reference rates of the general population in Taiwan by the observed  
19 person-years at risk in each stratum. The total observed number and total expected number of

1 cancers were calculated by summing the numbers in all strata. Then, the SIR was calculated  
2 by dividing total observed cancers (in the numerator) by total expected cancers (in the  
3 denominator).

4 The 95% confidence interval and two-tailed *P*-values were calculated under the  
5 assumption that the observed cancers followed a Poisson distribution. Assuming that an  
6 exposure requires a minimum induction period before it can cause cancer, we set lag periods  
7 to prevent the recent exposure contribute to the cumulative level of exposure. At calculating  
8 the incidence rate of cancer, exposure periods which occur within the lag period are not  
9 accumulated into the person years at risk and cancers occur within the lag period are grouped  
10 into a non-occupational exposure group to herbs.<sup>22</sup> The urological cancers progressed 3–15  
11 years depending on the cumulative dose of AA.<sup>23, 24</sup> Under the assumption that herbalists  
12 might have chronic and low dose exposure to herbs containing AA, sensitivity analysis with  
13 ten- and fifteen-year lag periods was performed in calculating SIR for urological cancers. In  
14 this study, the urological cancer included malignant neoplasm of bladder (ICD-9: 188) and  
15 malignant neoplasm of kidney and other and unspecified urinary organs (ICD-9: 189). The  
16 SIR for malignant neoplasm of prostate (ICD-9: 185) was calculated separately and was not  
17 included in urological cancer.

18

## 19 **Results**



1           The cohort consisted of 6,555 Chinese herbalists. After excluding five herbalists with  
2   missing employment data, this study finally enrolled 6,550 herbalists (3,093 men and 3,457  
3   women) for analysis. A total of 59,856 male person-years and 65,591 female person-years  
4   were accrued during the observation period. Among the 203 newly-diagnosed cases of cancer  
5   in the follow-up period, 30 cases were urological cancers. A positive association between  
6   exposure duration and the risk of urological cancer was illustrated by the trend of increased  
7   incidence rate of urological cancer for longer exposure duration, as shown in Figure 1. After  
8   controlling the confounding effect of age by adjusted to the gender-, age-, and  
9   calendar-time-specific reference rates of general population, the SIR was still significantly  
10   higher for all urological cancers (SIR = 3.51, 95% CI 2.37- 5.01) in herbalists. When we  
11   further stratified urological cancers by location, the SIR for kidney and upper urinary tract  
12   cancers (SIR = 4.24, 95% CI 2.47 - 6.80) was higher than the SIR for bladder cancer (SIR =  
13   2.86, 95% CI 1.52- 4.89). If we stratified by gender, the SIRs for all urological cancers,  
14   kidney and upper urinary tract cancer, or bladder cancer were all significantly increased in  
15   male herbalists with a 10-year lag period. With a 15-year lag period, male herbalists also had  
16   significantly elevated SIRs for all urological cancers, or kidney and upper urinary tract cancer.  
17   The SIRs for all urological cancers, kidney and upper urinary tract cancer, or bladder cancer  
18   in female herbalists with 10- and 15-year lag periods were all significantly increased and  
19   higher than those in male herbalists, as summarized in Table 2. Among cases of urological

1 cancers, most of them were, histologically, transitional cell carcinoma (93.1%). The mean age  
2 at diagnosis for urothelial carcinoma was 51.6 years, and approximately half of urothelial  
3 carcinomas (51.9%) were in the upper urinary tract (Table 3).

4

## 5 **Discussion**

6 The role of Chinese herbal drugs in the pathogenesis of kidney disease and urological  
7 cancer has attracted much interest in recent years, and virtually nothing is known about the  
8 health risks for workers chronically exposed to them. Consistent with our observation that  
9 male herbalists have a high exposure to herbs containing AA at work, this study provides  
10 evidence that male herbalists have increased risk of upper urinary tract urothelial carcinoma  
11 and shows that changing the lag period did not change the risk estimates (Table 1 and 2).

12 Yet we must rule out other alternative explanations before proposing any new hypothesis.  
13 Cigarette smoking is a major risk factor for urothelial carcinoma.<sup>25</sup> However, the prevalence  
14 of cigarette smoking was much smaller in herbalists (17.1%) than in other Taiwanese workers  
15 (26.7%).<sup>26, 27</sup> Thus, we believe that smoking is not the responsible agent. Long term use of  
16 analgesics is also another important risk factor.<sup>28</sup> Based on deeply rooted beliefs in the  
17 efficacy of Chinese medicine, herbalists do not typically prescribe Western medicines except  
18 in cases of severe illness. Indeed, only 2.9% of herbalists reported chronic use of analgesics<sup>26</sup>  
19 in comparison with 7.28% among the general population of Taiwan that had been prescribed

1 with more than 501 pills of NSAID (non-steroidal anti-inflammatory drugs) during  
2 1997–2002 based on the re-imburement database of National Health Insurance.<sup>29</sup> Use of  
3 analgesics cannot therefore account for the increased risk in herbalists. Arsenic is a  
4 carcinogen associated with urological cancer, and its concentration is known to be high in  
5 artesian-well water from some areas where black-foot disease is endemic.<sup>30, 31</sup> We checked  
6 the addresses of individuals with urological cancer, and none of them lived in the regions  
7 with contaminated artesian-well water. Thus drinking arsenic-contaminated water is probably  
8 not related to the increased risk.

9 As summarized in Tables 3, urological cancers among herbalists (compared to the  
10 general population of Taiwan) are mainly transitional cell carcinoma and more likely to occur  
11 in the upper urinary tract. The histological pattern and location are similar to AA-related  
12 urological cancers reported in Belgium, and are different from the urological cancers (in  
13 general) reported in Taiwan.<sup>9, 24, 32</sup> AA is derived from extracts of *Aristolochia*, *Bragantia*,  
14 and *Asarum* species, and is a common ingredient in many Chinese herbs, such as Madouling  
15 (*Aristolochia debilis*), Tianxianteng (*Aristolochia contorta*), Qingmuxiang (*Aristolochia*  
16 *cucurbitifolia*), Guangfangji (*Aristolochia fangji*), Guanmutong (*Aristolochia manshuriensis*),  
17 and Xixin (*Radix et Rhizoma Asari*).<sup>10-13</sup> As the histological pattern and location of the  
18 urological cancers in our sample are similar to those of AA-related urological cancers, we  
19 postulate that the increased risk among herbalists might be related to their chronic exposure

1 to Chinese herbs, which sometimes contain AA.

2       Based on our survey of herbalists in many traditional Chinese herbal stores, we suspect  
3 two possible exposure routes: (1) Ingestion of herbal powders or powder-contaminated food.  
4 Traditional Chinese herbal stores are usually small enterprises. In the past, workers usually  
5 participate in all procedures (cutting, drying, grinding, processing and packing), all of which  
6 generate lots of dust. Herbal powders may be inhaled, deposited in the oral pharynx, and then  
7 swallowed. Moreover, herbalists usually work and live in herbal stores. Many of their  
8 activities are performed in the backyard and there is no distinction between the dining room  
9 and workplace, so food may be contaminated by herbal powders. (2) Habitual use of herbal  
10 drugs. Herbalists generally prefer to use herbal drugs for treating all illnesses, because they  
11 are considered natural, mild and harmless. To promote the Yin-Yang balance according to the  
12 theory of Chinese medicine,<sup>33-35</sup> many herbalists also take daily herbal tonics to improve their  
13 state of well-being. Therefore, the use of herbal drugs is more prevalent in herbalists than in  
14 the general population.<sup>19</sup> In 2003, the Committee on Chinese Medicine and Pharmacy of the  
15 Department of Health issued a regulation prohibiting the use of herbal drugs containing  
16 Madouling, Tianxianteng, Qingmuxiang, Guangfangji and Guanmutong. But earlier exposure  
17 to herbal drugs containing AA may account for the increased risk of urological cancer  
18 observed in herbalists.

19       Some people might query that herbalists might had started their work with herbs before

1 1985 when the Chinese Herbalist Union was not established, and traditional herbal stores are  
2 usually family owned businesses so that many herbalists may contact herbs as a child. Thus,  
3 the actual person-years at risk might be greater than the number reported. But if we had  
4 obtained earlier employment data and extended the observation period, the number of cases  
5 reported and person-years at risk would simultaneously become larger. Since the risk of  
6 exposure to herbs probably containing AA did not change substantially before 2003, the  
7 estimates of SIR would not differ significantly before and after the year of 1985. Another  
8 potential confounder is the possibility that cases of urological cancer existed at the time when  
9 the herbalists joined the union and were insured. However, the estimates were not affected by  
10 setting lag period (10 and 15 years; Table 2) and suggested that the factor was not a  
11 confounder. Even though some family members of herbalists may insure the Labour  
12 Insurance through the Chinese Herbalist Union, and they have another or no job. But they  
13 live in herbal stores and consequently may also had been exposed to herbal dusts. We think  
14 that this potential limitation in classification had no effect on our results. As Chinese herbal  
15 drugs have been widely used in Taiwan with more than 39.3% of general population having  
16 been prescribed AA-containing Chinese herbal products from a national survey,<sup>36</sup> many  
17 Taiwanese people (categorized as non-exposed) could have been exposed to AA. This  
18 potential misclassification might have resulted in an underestimate of the SIRs for urological  
19 cancers in this study. Thus, the actual risk in Chinese herbalists may be greater than our

1 estimate.

2 This study showed that the risk of urological cancers was higher in female herbalists  
3 than male herbalists. In the Belgian cohort, all patients with AA-related urothelial carcinoma  
4 were women who took slimming regimens.<sup>23, 24</sup> Our another national survey using the data of  
5 the National Health Insurance from 1997 to 2003 found that most patients taking  
6 AA-containing Chinese herbal products were female.<sup>36</sup> Similar findings in a medical center  
7 of China showed that the majority of renal transplant recipients with urothelial carcinoma and  
8 had history of taking Chinese herbs containing AA were female.<sup>17</sup> These findings all indicate  
9 more frequent use of herbs in women might be the cause of higher risk. But in the endemic of  
10 the Balkan Peninsula, residents ate bread contaminated by AA and then developed upper tract  
11 urothelial carcinoma; female had higher risk than male.<sup>37-39</sup> Our another retrospective study  
12 in Taiwan also found that young women were more likely to develop chronic kidney disease  
13 if taking more than the threshold cumulative dose of herbs containing AA.<sup>29</sup> Therefore, we  
14 could not rule out the possibility that female gender is more susceptible to AA-related renal  
15 damage, and the alternative explanation could explain why female herbalists had higher risk  
16 of urological cancers than male herbalists that theoretically had higher exposure to herbs  
17 containing AA at work. We recommend future study to clarify them.

18 Some potential limitations of this study are inherent in retrospective cohort studies. In  
19 Taiwan, raw Chinese herbs are mainly imported from mainland China, and many Chinese

1 herbs from China are reported to be contaminated by heavy metals, including arsenic.<sup>19, 40-44</sup>  
2 We can't rule out the possibility that arsenic contamination might play a role in the increased  
3 risk of urological cancer among herbalists. Moreover, this study used the length of  
4 employment as a surrogate for the degree of exposure to herbs. Thus more epidemiological  
5 data on the occupational exposure, environmental exposure, lifestyle and medical history are  
6 needed to clarify causality.

7 Since 2003, the Committee on Chinese Medicine and Pharmacy has prohibited the use  
8 of Madouling, Tianxianteng, Qingmuxiang, Guangfangji and Guanmutong, and herbalists are  
9 becoming aware of the hazards of aristolochic acids. Moreover, the procedures of  
10 manufacturing and processing herbs have been shifted to mainland China in this decade. By  
11 our interview survey, most herbal stores do not process herbs but only sell herbal products  
12 now. We suspect the incidence of urological cancer among herbalists would decrease  
13 gradually in the next decade because the occurrence of cancer may develop years after  
14 discontinuation of exposure. Although there was still an increased trend of upper tract  
15 urothelial carcinoma in general population of Taiwan from the National Cancer Registry in  
16 these years, a higher risk in the herbalists was proved after standardization of their gender,  
17 age and period. Our another study using the data from the National Health Insurance in  
18 Taiwan between 1997 and 2003 showed that one-third of people in Taiwan had been  
19 prescribed with Chinese herbs that were potentially adulterated by AA.<sup>36</sup> A more strict

1 prohibition including all herbs contaminated with AA is warranted to cease the trend.

2 In conclusion, the significant risk of urothelial carcinoma noted in male herbalists  
3 increases our suspicion that urothelial carcinoma is an occupational disease that renders  
4 regular health assessment of herbalists an urgent necessity.

5

## 6 **Acknowledgements**

7 The study was carried out independently without any sponsorship. All authors declare that  
8 they have no potential conflict of interest or any financial and personal relationships that  
9 might bias their work.

10

11



1 **References**

- 2 1. Tyler VE. Herbal medicine: from the past to the future. *Public Health Nutr* 2000;3:447-52.
- 3 2. Chen FP, Chen TJ, Kung YY, et al. Use frequency of traditional Chinese medicine in  
4 Taiwan. *BMC Health Serv Res* 2007;7:26.
- 5 3. Hong CD. Complementary and alternative medicine in Korea: current status and future  
6 prospects. *J Altern Complement Med* 2001;7 Suppl 1:S33-40.
- 7 4. Yamashita H, Tsukayama H, Sugishita C. Popularity of complementary and alternative  
8 medicine in Japan: a telephone survey. *Complement Ther Med* 2002;10:84-93.
- 9 5. Chung V, Wong E, Woo J, et al. Use of traditional Chinese medicine in the Hong Kong  
10 special administrative region of China. *J Altern Complement Med* 2007;13:361-7.
- 11 6. Lee CH, Chen JJ, Liang WM. Attitudes and intentions of patients toward integrated  
12 Chinese and Western medicine in Taiwan. *J Altern Complement Med* 2006;12:233-6.
- 13 7. Liu CT. Health care systems in transition. II. Taiwan, Part I. A general overview of the  
14 health care system in Taiwan. *J Public Health Med* 1998;20:5-10.
- 15 8. Chi C, Lee JL, Lai JS, et al. The practice of Chinese medicine in Taiwan. *Soc Sci Med*  
16 1996;43:1329-48.
- 17 9. Nortier JL, Martinez MC, Schmeiser HH, et al. Urothelial carcinoma associated with the  
18 use of a Chinese herb (*Aristolochia fangchi*). *N Engl J Med* 2000;342:1686-92.
- 19 10. Zhang C, Wang X, Shang M, et al. Simultaneous determination of five aristolochic acids

- 1 and two aristololactams in Aristolochia plants by high-performance liquid chromatography.  
2 *Biomed Chromatogr* 2006;20:309-18.
- 3 11. Wu KM, Farrelly JG, Upton R, et al. Complexities of the herbal nomenclature system in  
4 traditional Chinese medicine (TCM): lessons learned from the misuse of  
5 Aristolochia-related species and the importance of the pharmaceutical name during  
6 botanical drug product development. *Phytomedicine* 2007;14:273-9.
- 7 12. Jong TT, Lee MR, Hsiao SS, et al. Analysis of aristolochic acid in nine sources of Xixin,  
8 a traditional Chinese medicine, by liquid chromatography/atmospheric pressure chemical  
9 ionization/tandem mass spectrometry. *J Pharm Biomed Anal* 2003;33:831-7.
- 10 13. Drew AK, Whyte IM, Bensoussan A, et al. Chinese herbal medicine toxicology database:  
11 monograph on Herba Asari, "xi xin". *J Toxicol Clin Toxicol* 2002;40:169-72.
- 12 14. Lai MN, Wang SM, Chen PC, et al. Population-based case-control study of Chinese  
13 herbal products containing aristolochic acid and urinary tract cancer risk. *J Natl Cancer*  
14 *Inst* 2009;102:1-8.
- 15 15. Yang CS, Lin CH, Chang SH, et al. Rapidly progressive fibrosing interstitial nephritis  
16 associated with Chinese herbal drugs. *Am J Kidney Dis* 2000;35:313-8.
- 17 16. Chang CH, Wang YM, Yang AH, et al. Rapidly progressive interstitial renal fibrosis  
18 associated with Chinese herbal medications. *Am J Nephrol* 2001;21:441-8.
- 19 17. Li XB, Xing NZ, Wang Y, et al. Transitional cell carcinoma in renal transplant recipients:

- 1 a single center experience. *Int J Urol* 2008;15:53-7.
- 2 18. Yang HY, Wang JD, Lo TC, et al. Increased mortality risk for cancers of the kidney and  
3 other urinary organs among Chinese herbalists. *J Epidemiol* 2009;19:17-23.
- 4 19. Chang HC, Tsai KH. Characteristics of Chinese herbalists in Taiwan. *Disquisitions on the*  
5 *Past and Present* 2004;11:96-114. [in Chinese]
- 6 20. Chu PC, Wang JD, Hwang JS, et al. Estimation of life expectancy and the expected years  
7 of life lost in patients with major cancers: extrapolation of survival curves under  
8 high-censored rates. *Value Health* 2008;11:1102-9.
- 9 21. Department of Health of the executive branch of the central government. Taiwan Cancer  
10 Registry. Available [http:// crs.cph.ntu.edu.tw/main.php?Page=N1](http://crs.cph.ntu.edu.tw/main.php?Page=N1) Accessed September 4,  
11 2009.
- 12 22. National Institute for Occupational Safety and Health. Life Table Analysis System.  
13 Available: <http://www.cdc.gov/niosh/LTAS/default.html> Accessed September 4, 2009.
- 14 23. Cosyns JP, Jadoul M, Squifflet JP, et al. Urothelial lesions in Chinese-herb nephropathy.  
15 *Am J Kidney Dis* 1999;33:1011-7.
- 16 24. Lemy A, Wissing KM, Rorive S, et al. Late onset of bladder urothelial carcinoma after  
17 kidney transplantation for end-stage aristolochic acid nephropathy: a case series with  
18 15-year follow-up. *Am J Kidney Dis* 2008;51:471-7.
- 19 25. Zeegers MP, Tan FE, Dorant E, et al. The impact of characteristics of cigarette smoking

- 1 on urinary tract cancer risk: a meta-analysis of epidemiologic studies. *Cancer*  
2 2000;89:630-9.
- 3 26. Lo TC. A case-control study of chronic renal disease on herbalists in Taiwan  
4 [Dissertation]. Taipei, Taiwan: Taiwan University 2003.
- 5 27. Liang WM, Kuo HW, Wang CB. Prevalence of tobacco smoking, drinking and betel nut  
6 chewing among Taiwanese workers in 1999. *Mid-Taiwan J Med* 2002;7:146-54.
- 7 28. Gago-Dominguez M, Yuan JM, Castelao JE, et al. Regular use of analgesics is a risk  
8 factor for renal cell carcinoma. *Br J Cancer* 1999;81:542-8.
- 9 29. Lai MN, Lai JN, Chen PC, et al. Increased risks of chronic kidney disease associated with  
10 prescribed Chinese herbal products suspected to contain aristolochic acid. *Nephrology*  
11 (Carlton) 2008;14:227-34.
- 12 30. Chiou HY, Chiou ST, Hsu YH, et al. Incidence of transitional cell carcinoma and arsenic  
13 in drinking water: a follow-up study of 8,102 residents in an arseniasis-endemic area in  
14 northeastern Taiwan. *Am J Epidemiol* 2001;153:411-8.
- 15 31. Chen CJ, Hsu LI, Wang CH, et al. Biomarkers of exposure, effect, and susceptibility of  
16 arsenic-induced health hazards in Taiwan. *Toxicol Appl Pharmacol* 2005;206:198-206.
- 17 32. Department of Health of the executive branch of the central government. Annual report of  
18 Taiwan Cancer Registry in 2004. Available: [crs.cph.ntu.edu.tw/main.php?Page=A5](http://crs.cph.ntu.edu.tw/main.php?Page=A5).  
19 Accessed September 4, 2009.

- 1 33. Chan K. Progress in traditional Chinese medicine. *Trends Pharmacol Sci* 1995;16:182-7.
- 2 34. Cheng JT. Review: drug therapy in Chinese traditional medicine. *J Clin Pharmacol*
- 3 2000;40:445-50.
- 4 35. Unschuld PU. *Huang Di Nei Jing Su Wen: Nature, Knowledge and Imagery in an Ancient*
- 5 *Chinese Medical Text*. London: University of California Press. Ltd, 2003.
- 6 36. Hsieh SC, Lin IH, Tseng WL, et al. Prescription profile of potentially aristolochic acid
- 7 containing Chinese herbal products: an analysis of National Health Insurance data in
- 8 Taiwan between 1997 and 2003. *Chin Med* 2008;23:13.
- 9 37. Arlt VM, Ferluga D, Stiborova M, et al. Is aristolochic acid a risk factor for Balkan
- 10 endemic nephropathy-associated urothelial cancer? *Int J Cancer* 2002;101:500-2.
- 11 38. Hranjec T, Kovac A, Kos J, et al. Endemic nephropathy: the case for chronic poisoning by
- 12 aristolochia. *Croat Med J* 2005;46:116-25.
- 13 39. Grollman AP, Jelaković B. Role of environmental toxins in endemic (Balkan)
- 14 nephropathy. *J Am Soc Nephrol* 2007;18:2817-23.
- 15 40. Koh HL, Woo SO. Chinese proprietary medicine in Singapore: regulatory control of toxic
- 16 heavy metals and undeclared drugs. *Drug Saf* 2000;23:351-62.
- 17 41. Wu TN, Yang KC, Wang CM, et al. Lead poisoning caused by contaminated Cordyceps, a
- 18 Chinese herbal medicine: two case reports. *Sci Total Environ* 1996;182:193-5.
- 19 42. Au AM, Ko R, Boo FO, et al. Screening methods for drugs and heavy metals in Chinese

- 1 patent medicines. *Bull Environ Contam Toxicol* 2000;65:112-9.
- 2 43. Ernst E, Thompson Coon J. Heavy metals in traditional Chinese medicines: a systematic  
3 review. *Clin Pharmacol Ther* 2001;70:497-504.
- 4 44. Cheung TP, Xue C, Leung K, et al. Aristolochic acids detected in some raw Chinese  
5 medicinal herbs and manufactured herbal products--a consequence of inappropriate  
6 nomenclature and imprecise labeling? *Clin Toxicol* 2006;44:371-8.

7

8

9

1 **Figure legends**

2 Figure 1. The incidence rate of urological cancer stratified by exposure duration. Figure  
3 shows positive association between exposure duration and the risk of urological cancers.

4

5 **Tables**

6 Table 1. Standardized incidence ratio (SIR) for different types of cancer in Chinese herbalists

7 Table 2. Standardized incidence ratio (SIR) for urological cancers, stratified by gender and  
8 different lag periods

9 Table 3. Comparison with urological cancers classified by location and histological patterns

10


11 **Supplementary Material**

12 Table S1. Urological cancers among Chinese herbalists. Table lists the cancer types, gender,  
13 age, cancer site and histological types of the patients of urological cancers among Chinese  
14 herbalists.

15 Table S2. Standardized incidence ratios (SIRs) for cancers in Chinese herbalists, data are  
16 stratified by gender.

17

18



1

2 Figure 1. The incidence rate of urological cancer stratified by exposure duration. Figure

3 shows positive association between exposure duration and the risk of urological cancers.

4

5



1 **Table 1.** Standardized incidence ratio (SIR) for different types of cancer in Chinese herbalists

| Cancer site (ICD-10)                           | Observed<br>no. | Expected<br>no.§ | SIR (95% CI)       |
|--|-----------------|------------------|--------------------|
| All cancers                                    | 203             | 236.06           | 0.86* (0.75-0.99)  |
| Nasopharynx (C11)                              | 15              | 12.29            | 1.22 (0.68-2.01)   |
| Esophagus (C15)                                | 3               | 3.95             | 0.76 (0.16-2.22)   |
| Stomach (C16)                                  | 9               | 13.26            | 0.68 (0.31-1.29)   |
| Colon and rectum (C18-21)                      | 13              | 22.76            | 0.57* (0.30-0.98)  |
| Liver and intrahepatic bile ducts(C22)         | 21              | 31.04            | 0.68 (0.42-1.03)   |
| Pancreas (C25)                                 | 6               | 2.63             | 2.28 (0.83-4.97)   |
| Larynx (C32)                                   | 2               | 1.72             | 1.16 (0.14-4.19)   |
| Trachea, bronchus, and lung (C33-34)           | 13              | 18.63            | 0.70 (0.37-1.19)   |
| Breast (C50)                                   | 24              | 25.92            | 0.93 (0.59-1.38)   |
| Urinary organs (C64-68)                        | 30              | 8.55             | 3.51**(2.37-5.01)  |
| Kidney and upper urinary tract<br>(C64-66,C68) | 17              | 4.00             | 4.24** (2.47-6.80) |
| Bladder (C67)                                  | 13              | 4.55             | 2.86** (1.52-4.89) |
| Eye (C69)                                      | 2               | 0.23             | 8.53* (1.03-30.79) |
| Brain (C71)                                    | 1               | 2.67             | 0.37 (0.01-2.08)   |

|   |   |      |                   |
|---|---|------|-------------------|
| Other parts of nervous system<br>(C70,C72)                | 1 | 0.27 | 3.37 (0.09-20.73) |
| Thyroid gland (C73)                                       | 4 | 5.52 | 0.73 (0.20-1.85)  |
| Connective tissue (C46.1, C49)                            | 1 | 1.43 | 0.70 (0.02-3.88)  |
| Leukemia and aleukemia (C91.0-91.3,<br>C91.5-91.9,C92-95) | 4 | 5.05 | 0.79 (0.22-2.02)  |

---

- 1 Note: ICD-10 = International Classification of Diseases, 10<sup>th</sup> Revision.
- 2 CI = confidence interval.
- 3 §The expected number of cancer patients was calculated based upon the age and calendar
- 4 year-specific incidence rates of the general population of Taiwan with 10-year lag period.
- 5 \* two tailed P < 0.05
- 6 \*\* two tailed P < 0.01
- 7

**Table 2.** Standardized incidence ratio (SIR) for urological cancers, stratified by gender and different lag periods

| Cancer site (ICD-10)                      | 10-year lag |                    | 15-year lag |                    |
|---|-------------|--------------------|-------------|--------------------|
|   | No.         | SIR (95% CI)       | No.         | SIR (95% CI)       |
| <b>Male</b>                               |             |                    |             |                    |
| All urinary organs (C64-68)               | 14          | 2.45**(1.34-4.10)  | 14          | 2.47**(1.35-4.14)  |
| Kidney & upper urinary tract (C64-66,C68) | 7           | 2.96**(1.19-6.11)  | 7           | 2.99**(1.20-6.17)  |
| Bladder (C67)                             | 7           | 2.08(0.83-4.29)    | 7           | 2.10(0.84-4.33)    |
| <b>Female</b>                             |             |                    |             |                    |
| All urinary organs (C64-68)               | 16          | 5.66**(3.23-9.19)  | 15          | 5.39**(3.01-8.89)  |
| Kidney & upper urinary tract (C64-66,C68) | 10          | 6.09**(2.91-11.19) | 9           | 5.58**(2.55-10.59) |
| Bladder (C67)                             | 6           | 5.06**(1.85-11.02) | 6           | 5.13**(1.87-11.16) |

Note: No. = observed numbers of cancer patient, ICD-10 = International Classification of Diseases, 10<sup>th</sup> Revision.

CI = confidence interval.

\*\* two tailed P < 0.01

**Table 3.** Comparison with urological cancers classified by location and histological patterns

|                                    | Urological cancers<br>in herbalists<br>(n=30)§ | Urological cancers<br>in Belgian cohort†<br>(n=38) | Urological cancers<br>in Taiwan reported<br>in 2004¶<br>(n=3,541) |
|------------------------------------|--|--|---|
| <b>Location</b>                    |  |  |   |
| Kidney parenchyma (%)              | 3 (10.0)                                       | 0  | 628 (17.7)  |
| Pelvis and ureter (%)              | 14 (46.7)                                      | 17 (44.7)  | 1055 (29.8)   |
| Bladder (%)                        | 13 (43.3)                                      | 15 (39.5)  | 1858 (52.5)   |
| <b>Histological group</b>          |  |  |   |
| Renal cell carcinoma<br>(%)        | 2 (6.9)  | 0  | 502 (14.8)  |
| Transitional cell<br>carcinoma (%) | 27 (93.1)                                      | 32 (100)   | 2654 (78.4)   |
| Adenocarcinoma (%)                 | -  | 0  | 70 (2.1)  |
| Squamous cell<br>carcinoma (%)     | -  | 0  | 46 (1.4)  |
| Others (%)                         | -  | 0  | 113 (3.3)   |

§ One case of urological cancer had no microscopic confirmation and was excluded from analysis.

† Reference 24

¶ Reference 32